Study Summary
The primary purpose of this study is to determine safety, feasibility, and the Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) of CD22 Chimeric Antigen Receptor T-Cell Therapy (CART) cells when administered 28 to 42 days after an infusion of a commercial CAR called Tisagenlecleucel, to children and young adults with relapsed or refractory B-cell leukemia.
Interested in this trial?
Submit an InquiryInterventions
CD22CART infusionDRUG
CD22CART will be administered after Standard of Care (SOC) administration of tisagenlecleucel.
TisagenlecleucelDRUG
All enrolled participants will receive lymphodepletion followed by standard of care tisagenlecleucel infusion.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Stanford University | Palo Alto | California | United States |